Chronic renal failure syndrome

Summary

Chronic renal failure syndrome (MONDO:0024327) is a disease and 562 clinical trials. Top therapeutic interventions include peginesatide, cinacalcet, and lanthanum carbonate. A subtype of kidney failure — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 562

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chronic renal failure syndrome
Mondo ID	MONDO:0024327
MeSH	D051436
NCIT	C9438
SNOMED CT	90688005
UMLS	C0022661
MedGen	9637
Is cancer (heuristic)	no

Also known as: chronic kidney failure · Chronic renal disease · chronic renal failure · chronic renal failure disease · CRF - chronic renal failure · kidney failure, chronic

Disease family

This is a subtype of kidney failure. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › kidney failure › chronic renal failure syndrome

Related subtypes (2): acute kidney injury, uremia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 562.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	315
PHASE4	79
PHASE3	53
PHASE2	52
PHASE1	41
PHASE1/PHASE2	12
PHASE2/PHASE3	7
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05719376	PHASE4	NOT_YET_RECRUITING	The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes
NCT00035178	PHASE4	COMPLETED	Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
NCT00044720	PHASE4	COMPLETED	Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
NCT00091481	PHASE4	COMPLETED	Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis
NCT00111995	PHASE4	COMPLETED	Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis
NCT00124969	PHASE4	COMPLETED	Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure
NCT00139035	PHASE4	COMPLETED	Effects of Cyclosporine A on Pancreatic Insulin Secretion
NCT00160121	PHASE4	COMPLETED	Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease
NCT00204256	PHASE4	UNKNOWN	Intravenous Iron in Patients With Anemia of Chronic Kidney Disease
NCT00212758	PHASE4	COMPLETED	A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
NCT00224042	PHASE4	COMPLETED	Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents
NCT00224055	PHASE4	COMPLETED	Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients
NCT00224081	PHASE4	COMPLETED	DRIVE Trial (Dialysis Patients’ Response to Intravenous [IV] Iron With Elevated Ferritin)
NCT00235287	PHASE4	UNKNOWN	Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
NCT00244530	PHASE4	COMPLETED	Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery
NCT00255619	PHASE4	COMPLETED	Open Label Trial to Establish the Equivalence Between ANDY-Disc® and Ultrabag® in Patients on CAPD.
NCT00257283	PHASE4	COMPLETED	Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis
NCT00291603	PHASE4	COMPLETED	Short Term Effects of FX Dialysers on QOL and Inflammation
NCT00298441	PHASE4	COMPLETED	Efficacy of Intravenous Iron Administration in Hemodialysis Patients
NCT00307996	PHASE4	COMPLETED	The Effect of CoQ10 Administration on Hemodialysis Patients
NCT00317005	PHASE4	COMPLETED	Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events
NCT00334204	PHASE4	TERMINATED	Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?
NCT00338000	PHASE4	COMPLETED	EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure
NCT00354692	PHASE4	COMPLETED	Effect of Two Iron Preparations on Protein in the Urine
NCT00379899	PHASE4	COMPLETED	ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
NCT00430924	PHASE4	COMPLETED	Inhibition of Aldosterone in Patients With Chronic Renal Disease
NCT00438295	PHASE4	COMPLETED	Temperature Control During Dialysis Treatment
NCT00438503	PHASE4	COMPLETED	Glucose in Dialysis Water in Diabetics With Chronic Renal Failure
NCT00439023	PHASE4	COMPLETED	Glucose in Dialysis Water in Non-diabetics
NCT00456859	PHASE4	COMPLETED	Carbonaceous Oral Adsorbent’s Effects on Progression of Chronic Kidney Disease
NCT00493194	PHASE4	UNKNOWN	Fibrosis in Renal Allografts
NCT00501475	PHASE4	UNKNOWN	NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED
NCT00514813	PHASE4	TERMINATED	Dynepo Long-Term Safety Study
NCT00528788	PHASE4	COMPLETED	How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
NCT00548912	PHASE4	WITHDRAWN	Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease
NCT00629122	PHASE4	COMPLETED	Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation
NCT00716001	PHASE4	UNKNOWN	Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure
NCT00717379	PHASE4	COMPLETED	Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation
NCT00926562	PHASE4	COMPLETED	A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients
NCT00965094	PHASE4	COMPLETED	Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PEGINESATIDE	4	13
CINACALCET	4	12
LANTHANUM CARBONATE	4	8
SEVELAMER	4	6
SIROLIMUS	4	6
ACETYLCYSTEINE	4	3
BELATACEPT	4	3
DARBEPOETIN ALFA	4	3
ENALAPRIL	4	3
EPOETIN ALFA	4	3
IODIXANOL	4	3
TACROLIMUS ANHYDROUS	4	3
TOLVAPTAN	4	3
ALPROSTADIL	4	2
CYCLOSPORINE	4	2
DACLIZUMAB	4	2
DOXERCALCIFEROL	4	2
EVEROLIMUS	4	2
FERROUS SULFATE	4	2
IOPROMIDE	4	2
IRON SUCROSE	4	2
PENTOXIFYLLINE	4	2
SEVELAMER HYDROCHLORIDE	4	2
SOMATROPIN	4	2
SPIRONOLACTONE	4	2
ALEMTUZUMAB	4	1
ALISKIREN	4	1
AMLODIPINE	4	1
ARGATROBAN	4	1
ASCORBIC ACID	4	1